Search

Johanna Joyce, of the Sloan Kettering Institute's Cancer Biology and Genetics Program, has been named the first incumbent of a Geoffrey Beene Junior Faculty Chair.

… Sunday, April 1, 2007 Summary Johanna Joyce, of the Sloan Kettering Institute’s Cancer Biology and Genetics Program, has been named the first incumbent of a Geoffrey Beene Junior Faculty Chair. Johanna Joyce, of the Sloan Kettering Institute’s Cancer Biology and Genetics Program , has been named the

Meet Ben Hegel, a senior program coordinator in the Sloan Kettering Institute. “My introduction to Pride in college was through a celebratory lens,” says Ben. “But my relationship to Pride has changed.” He still celebrates, but he points out that the Pride March is just that — a march, not a parade. “It was started by marginalized people who were marching for their rights.”

… Wednesday, June 23, 2021 Ben Hegel is a swimmer. He has loved the water since his boyhood in New Hampshire, where he spent summers jumping off a covered bridge into the local brook with friends — the kind of childhood activity that made his future husband ask him if he grew up in Mayberry, the iconic

Memorial Sloan Kettering Cancer Center (MSK) is accepting applications for the 2025 Cohort of the MSK Innovation Hub (iHub) Challenge program. Digital health companies with innovations leveraging AI to address critical issues in the drug discovery process are encouraged to apply.

… Wednesday, June 4, 2025 Memorial Sloan Kettering Cancer Center (MSK) is accepting applications for the 2025 Cohort of the MSK Innovation Hub (iHub) Challenge program. Digital health companies with innovations leveraging AI to address critical issues in the drug discovery process are encouraged to apply

A new treatment that selectively seeks out prostate cancer cells shows great promise for treating advanced forms of the disease.

… Thursday, June 3, 2021 Update: On March 23, 2022, the US Food and Drug Administration approved 177 Lu-PSMA-617 for prostate cancer that has spread and grown resistant to other drugs. “FDA approval of this therapy will enable even more people who had essentially been given death sentences to survive and

Meet Cesar Figueroa Ortiz, who says, “The mission of MSK really resonated with me, all the employees seemed very happy, and the patients said great things about their care.”

… Wednesday, October 13, 2021 For  Cesar Figueroa Ortiz , New York City is his long-awaited home. As a native of Bogotá, Colombia, he remembers stepping out of a subway station into Times Square several years ago and finding himself surrounded by throngs of people speaking multiple languages. “I had never

Memorial Sloan Kettering Cancer Center (MSK) is partnering with DigitasLBi and Phase2 to help expand MSK's digital reach.

… Thursday, June 19, 2014 Memorial Sloan Kettering Cancer Center (MSK) today announced the appointment of DigitasLBi as its digital agency of record and Phase2 as its Drupal technology partner. Memorial Sloan Kettering’s digital reach is significant, and the institution is viewed as one of the country’

Memorial Sloan Kettering and Quest Diagnostics announced a joint collaboration that will utilize MSK’s clinical and research insights into gene mutations associated with solid tumors.

… Sunday, June 1, 2014 Diagnostic insights into gene mutations in solid tumor cancers will aid therapy selection and prognosis for patients and advance research Memorial Sloan Kettering Cancer Center, the world’s oldest and largest private cancer center, and Quest Diagnostics (NYSE: DGX), the world’s leading

A protein detected in the urine of children with Wilms’ tumor led to the development of a test to improve diagnosis and treatment.

… Thursday, August 8, 2019 Summary Wilms’ tumor is the most common kidney cancer in children. Researchers have detected a protein called prohibitin in the urine of people with aggressive Wilms’ tumor. This discovery could help doctors identify people at risk for the cancer returning after treatment and

A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, regardless of prior CDK 4/6 inhibitors, ESR1 or PI3K pathway mutations.

… Wednesday, December 11, 2024 A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative (ER

The largest, most comprehensive study of its kind from Memorial Sloan Kettering Cancer Center finds that the biology of colorectal cancer in people under 50 is very similar to the disease in older people and more aggressive treatment of younger patients may not be warranted.

… Wednesday, August 18, 2021 Could colorectal cancer in people under 50 years old be biologically different and more aggressive than colorectal cancer in older people? That’s what some researchers have proposed as people in their 20s, 30s, and 40s face a disturbing rise in colorectal cancer — people who